6% Hydroxyethyl starch (130/0.4) vs Ringer's lactate preloading before spinal anaesthesia for Caesarean delivery: the randomized, double-blind, multicentre CAESAR trial ‡

Archive ouverte

Mercier, F.J. | Diemunsch, P. | Ducloy-Bouthors, A.-S. | Mignon, A. | Fischler, M. | Malinovsky, J.M. | Bolandard, F. | Aya, A.G. | Raucoules-Aimé, M. | Chassard, D. | Keita, H. | Rigouzzo, A. | Le Gouez, A. | Working Group, Caesar

Edité par CCSD ; Oxford University Press (OUP) -

International audience. BACKGROUND:Vasopressor administration is recommended to prevent hypotension during spinal anaesthesia (SA) for elective Caesarean delivery. We aimed to test the superior efficacy and ensure safety of a hydroxyethyl starch (HES) vs a Ringer's lactate (RL) preloading, when combined with a phenylephrine-based prophylaxis.METHODS:A total of 167 healthy parturients undergoing elective Caesarean delivery under SA were included in this multicentre, randomized, double-blind study. Patients received 500 ml of 6% HES (130/0.4)+500 ml of RL (HES group) or 1000 ml of RL (RL group) i.v. before SA. After SA, i.v. phenylephrine boluses were titrated when systolic arterial pressure (SAP) was below 95% of baseline. The primary outcome was the incidence of maternal hypotension (SAP <80% of baseline).RESULTS:The incidence of both hypotension and symptomatic hypotension (i.e. with dizziness, nausea/vomiting, or both) was significantly lower in the HES group vs the RL group: 36.6% vs 55.3% (one-sided P=0.025) and 3.7% vs 14.1%. There was no significant difference in total phenylephrine requirements [median (range): 350 (50-1800) vs 350 (50-1250) µg]. The decrease in maternal haemoglobin value the day after surgery was similar in the two groups [1.2 (1.0) vs 1.0 (0.9) g dl(-1)]. There was no detectable placental transfer of HES in six umbilical cord blood samples analysed in the HES group. Neonatal outcomes were comparable between the groups.CONCLUSIONS:Compared with a pure RL preloading, a mixed HES-RL preloading significantly improved prevention of both hypotension and symptomatic hypotension based on early phenylephrine bolus administration and did not induce adverse effects.CLINICAL TRIAL REGISTRATION:NCT00694343 (http://clinicaltrials.gov).

Consulter en ligne

Suggestions

Du même auteur

Recombinant human FVIIa for reducing the need for invasive second-line therapies in severe refractory postpartum hemorrhage: a multicenter, randomized, open controlled trial

Archive ouverte | Lavigne-Lissalde, G. | CCSD

International audience

[Prophylaxis of thromboembolic complications in obstetrics and gynaecology]

Archive ouverte | Benhamou, D. | CCSD

International audience. Venous thromboembolism is a leading cause of maternal mortality in many countries, including France. Most enquiries have repeatedly demonstrated that many deaths could be avoided, suggesting ...

[Anesthetic management of severe or worsening postpartum hemorrhage].. Prise en charge anesthésique d’une hémorragie du post-partum sévère ou résistant au traitement médical

Archive ouverte | Aya, A.G. | CCSD

International audience

Chargement des enrichissements...